{"id":16947,"date":"2020-08-17T12:27:56","date_gmt":"2020-08-17T04:27:56","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=16947"},"modified":"2020-08-17T15:02:26","modified_gmt":"2020-08-17T07:02:26","slug":"snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/","title":{"rendered":"Snapshot week 34\/2020<br> Response to TBE vaccination in transplant patients"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">Harrison et al.<br>Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.<br><em>npj Vaccines<\/em>, 2020;5:67. doi:10.1038\/s41541-020-00215-1<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Allogenic hematopoietic stem cell transplant (HSCT) and marrow graft recipients have an increased risk for infections due to delayed immune reconstitution, immunosuppressive therapy, and graft-versus-host disease. Therefore, various vaccinations are recommended for these patients, including vaccination for TBE for patients living in endemic areas, although no data on effectiveness in HSCT patients exist. A single-center study has been carried out to characterize the immune response to TBE vaccination one year after transplantation compared to healthy controls.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">One year after HSCT, the majority of patients (79%) still had neutralizing antibodies. However, a strong decline of NT titer before HSCT to one year after HSCT has been observed and all patients were boosted. HSCT patients had a reduced immune response to TBE vaccination, as only 35% of patients, but 93% of controls, exhibited an at least twofold increase of the NT four weeks after the second vaccination. Only patients without previous vaccination did not respond after the second TBE vaccination but received a protective antibody response after the third vaccination. Following vaccination, antibody response in HSCT patients was associated with CD+ cell count. NT test remains the gold standard for assessment of TBE specific humoral immunity in HSCT patients.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Harrison et al.Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.npj Vaccines, 2020;5:67. doi:10.1038\/s41541-020-00215-1 Allogenic hematopoietic stem cell transplant (HSCT) and marrow graft recipients have an increased risk for infections due to delayed immune reconstitution, immunosuppressive therapy, and graft-versus-host disease. Therefore, various vaccinations are recommended for these patients, including vaccination for TBE for patients living in endemic areas, although no data on effectiveness in HSCT patients exist. A single-center study has been carried out to characterize the immune response to TBE vaccination one year after transplantation compared to healthy controls. One year after HSCT, the majority of patients (79%) still had neutralizing antibodies. However, a strong decline of NT titer before HSCT to one year after HSCT has been observed and all patients were boosted. HSCT patients had a reduced immune response to TBE vaccination, as only 35% of patients, but 93% of controls, exhibited an at least twofold increase of the NT four weeks after the second vaccination. Only patients without previous vaccination did not respond after the second TBE vaccination but received a protective antibody response after the third vaccination. Following vaccination, antibody response in HSCT patients was associated with CD+ cell count. NT test remains the gold standard for assessment of TBE specific humoral immunity in HSCT patients.<\/p>\n","protected":false},"author":6,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[295,535,536,440,534],"coauthors":[81],"class_list":["post-16947","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-booster-vaccination","tag-hematopoietic-stem-cell-transplantation","tag-neutralizing-antibodies","tag-tbe-vaccination","tag-transplant-patients"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 34\/2020 Response to TBE vaccination in transplant patients - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 34\/2020 Response to TBE vaccination in transplant patients - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Harrison et al.Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.npj Vaccines, 2020;5:67. doi:10.1038\/s41541-020-00215-1 Allogenic hematopoietic stem cell transplant (HSCT) and marrow graft recipients have an increased risk for infections due to delayed immune reconstitution, immunosuppressive therapy, and graft-versus-host disease. Therefore, various vaccinations are recommended for these patients, including vaccination for TBE for patients living in endemic areas, although no data on effectiveness in HSCT patients exist. A single-center study has been carried out to characterize the immune response to TBE vaccination one year after transplantation compared to healthy controls. One year after HSCT, the majority of patients (79%) still had neutralizing antibodies. However, a strong decline of NT titer before HSCT to one year after HSCT has been observed and all patients were boosted. HSCT patients had a reduced immune response to TBE vaccination, as only 35% of patients, but 93% of controls, exhibited an at least twofold increase of the NT four weeks after the second vaccination. Only patients without previous vaccination did not respond after the second TBE vaccination but received a protective antibody response after the third vaccination. Following vaccination, antibody response in HSCT patients was associated with CD+ cell count. NT test remains the gold standard for assessment of TBE specific humoral immunity in HSCT patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-17T04:27:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-17T07:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Br\u00f6ker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Br\u00f6ker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/\"},\"author\":{\"name\":\"augustine\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2f903afeb7534df7457d2e3f6d30f64c\"},\"headline\":\"Snapshot week 34\\\/2020 Response to TBE vaccination in transplant patients\",\"datePublished\":\"2020-08-17T04:27:56+00:00\",\"dateModified\":\"2020-08-17T07:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/\"},\"wordCount\":227,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"booster vaccination\",\"hematopoietic stem cell transplantation\",\"neutralizing antibodies\",\"TBE vaccination\",\"transplant patients\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/\",\"name\":\"Snapshot week 34\\\/2020 Response to TBE vaccination in transplant patients - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2020-08-17T04:27:56+00:00\",\"dateModified\":\"2020-08-17T07:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 34\\\/2020 Response to TBE vaccination in transplant patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2f903afeb7534df7457d2e3f6d30f64c\",\"name\":\"augustine\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=ge035e25b3672069f7222fdb9b71e7000\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g\",\"caption\":\"augustine\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/augustine-augustine\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 34\/2020 Response to TBE vaccination in transplant patients - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 34\/2020 Response to TBE vaccination in transplant patients - TBE Book","og_description":"Harrison et al.Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.npj Vaccines, 2020;5:67. doi:10.1038\/s41541-020-00215-1 Allogenic hematopoietic stem cell transplant (HSCT) and marrow graft recipients have an increased risk for infections due to delayed immune reconstitution, immunosuppressive therapy, and graft-versus-host disease. Therefore, various vaccinations are recommended for these patients, including vaccination for TBE for patients living in endemic areas, although no data on effectiveness in HSCT patients exist. A single-center study has been carried out to characterize the immune response to TBE vaccination one year after transplantation compared to healthy controls. One year after HSCT, the majority of patients (79%) still had neutralizing antibodies. However, a strong decline of NT titer before HSCT to one year after HSCT has been observed and all patients were boosted. HSCT patients had a reduced immune response to TBE vaccination, as only 35% of patients, but 93% of controls, exhibited an at least twofold increase of the NT four weeks after the second vaccination. Only patients without previous vaccination did not respond after the second TBE vaccination but received a protective antibody response after the third vaccination. Following vaccination, antibody response in HSCT patients was associated with CD+ cell count. NT test remains the gold standard for assessment of TBE specific humoral immunity in HSCT patients.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/","og_site_name":"TBE Book","article_published_time":"2020-08-17T04:27:56+00:00","article_modified_time":"2020-08-17T07:02:26+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Michael Br\u00f6ker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Br\u00f6ker","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/"},"author":{"name":"augustine","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2f903afeb7534df7457d2e3f6d30f64c"},"headline":"Snapshot week 34\/2020 Response to TBE vaccination in transplant patients","datePublished":"2020-08-17T04:27:56+00:00","dateModified":"2020-08-17T07:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/"},"wordCount":227,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["booster vaccination","hematopoietic stem cell transplantation","neutralizing antibodies","TBE vaccination","transplant patients"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/","name":"Snapshot week 34\/2020 Response to TBE vaccination in transplant patients - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2020-08-17T04:27:56+00:00","dateModified":"2020-08-17T07:02:26+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2020-response-to-tbe-vaccination-in-transplant-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 34\/2020 Response to TBE vaccination in transplant patients"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2f903afeb7534df7457d2e3f6d30f64c","name":"augustine","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=ge035e25b3672069f7222fdb9b71e7000","url":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g","caption":"augustine"},"url":"https:\/\/tbenews.com\/tbe\/author\/augustine-augustine\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/16947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=16947"}],"version-history":[{"count":2,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/16947\/revisions"}],"predecessor-version":[{"id":16950,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/16947\/revisions\/16950"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=16947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=16947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=16947"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=16947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}